Leflunomide Tablet
Product Images NDC 62332-061

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 62332-061). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Leflunomide 10 mg

Leflunomide Tablets USP 10 mg oral tablet packaging label by Alembic Pharmaceuticals Inc. Contains 30 film-coated tablets. The label includes storage instructions, a warning to keep out of reach of children, and child-resistant packaging information. Manufactured by Alembic Pharmaceuticals Limited in India for Alembic Pharmaceuticals, Inc., Bedminster, NJ.*

FDA Label Image

Leflunomide 20 mg

Leflunomide Tablets USP 20 mg oral tablet label by Alembic Pharmaceuticals Inc. The label includes strength, quantity (30 tablets), NDC 62332-062-30, storage instructions, warnings, and manufacturer information for Alembic Pharmaceuticals Limited, India, and Alembic Pharmaceuticals, Inc., USA. The label is primarily white with blue and green design elements and includes a barcode.*

FDA Label Image

Figure 1 (Leflunomide Figure1)

A bar chart titled '% ACR 20 Responder at Endpoint' comparing the response percentages of Leflunomide (L), Methotrexate (M), Placebo (P), and Sulfasalazine (S) across three clinical trials with endpoints at 6 to 12 months. The y-axis indicates percentage response from -20 to 70.*

FDA Label Image

Figure 2 (Leflunomide Figure2)

A line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders over 12 months. The x-axis represents time in months (0 to 12) and the y-axis represents the percentage of responders (ranging from -10 to 70%). Three treatment groups are shown: PL (placebo) with a line of circles, MTX (methotrexate) with a line of squares, and LEF (leflunomide) with solid triangles. All groups show an increase in responders over time, with LEF and MTX reaching higher percentages than placebo.*

FDA Label Image

Figure 3 (Leflunomide Figure3)

A bar chart titled 'Change in Sharp Score' depicting progression over three trials with durations of 12 months, 6 months, and 12 months. The vertical axis represents progression, with values ranging from -10 to 8. Bars represent Leflunomide (L), methotrexate (M), sulfasalazine (S), and placebo (P) groups, with corresponding numeric values shown on each bar. Leflunomide and other treatments show varying degrees of change compared to placebo across trials.*

FDA Label Image

Figure 4 (Leflunomide Figure4)

A bar chart titled 'Change in Functional Ability Measure' showing data from three trials over 6 to 12 months. The chart compares functional ability changes measured by the HAQ Disability Index for Leflunomide (L), Methotrexate (M), Placebo (P), and Sulfasalazine (S). Data bars indicate improvement levels, with Leflunomide consistently showing greater improvement decline values compared to other treatments in each trial.*

FDA Label Image

Structure (Leflunomide Metabolite)

Chemical structure diagram of Leflunomide, showing its molecular formula including trifluoromethyl group, amide linkage, ketone, and cyano functional groups.*

FDA Label Image

Structure (Leflunomide Structure)

Chemical structure diagram of Leflunomide, showing the arrangement of atoms and bonds in the molecule as a 5-membered ring with attached functional groups, including a trifluoromethyl-substituted aromatic ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.